AU6623201A - Colchinol derivatives as angiogenesis inhibitors - Google Patents

Colchinol derivatives as angiogenesis inhibitors

Info

Publication number
AU6623201A
AU6623201A AU6623201A AU6623201A AU6623201A AU 6623201 A AU6623201 A AU 6623201A AU 6623201 A AU6623201 A AU 6623201A AU 6623201 A AU6623201 A AU 6623201A AU 6623201 A AU6623201 A AU 6623201A
Authority
AU
Australia
Prior art keywords
angiogenesis inhibitors
colchinol derivatives
colchinol
derivatives
angiogenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU6623201A
Inventor
Jean Claude Arnould
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angiogene Pharmaceuticals Ltd
Original Assignee
Angiogene Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiogene Pharmaceuticals Ltd filed Critical Angiogene Pharmaceuticals Ltd
Publication of AU6623201A publication Critical patent/AU6623201A/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/185Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/091Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/02Ortho- or ortho- and peri-condensed systems
    • C07C2603/04Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/30Ortho- or ortho- and peri-condensed systems containing three rings containing seven-membered rings
    • C07C2603/32Dibenzocycloheptenes; Hydrogenated dibenzocycloheptenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU6623201A 2000-07-07 2001-07-04 Colchinol derivatives as angiogenesis inhibitors Pending AU6623201A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00401977 2000-07-07
EP00401976 2000-07-07
PCT/GB2001/002964 WO2002008213A1 (en) 2000-07-07 2001-07-04 Colchinol derivatives as angiogenesis inhibitors

Publications (1)

Publication Number Publication Date
AU6623201A true AU6623201A (en) 2002-02-05

Family

ID=26073520

Family Applications (2)

Application Number Title Priority Date Filing Date
AU6623201A Pending AU6623201A (en) 2000-07-07 2001-07-04 Colchinol derivatives as angiogenesis inhibitors
AU2001266232A Ceased AU2001266232B2 (en) 2000-07-07 2001-07-04 Colchinol derivatives as angiogenesis inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2001266232A Ceased AU2001266232B2 (en) 2000-07-07 2001-07-04 Colchinol derivatives as angiogenesis inhibitors

Country Status (19)

Country Link
EP (1) EP1301498A1 (en)
JP (1) JP2004504391A (en)
KR (1) KR20030022264A (en)
CN (1) CN1255392C (en)
AU (2) AU6623201A (en)
BR (1) BR0112225A (en)
CA (1) CA2410562A1 (en)
CZ (1) CZ200331A3 (en)
EE (1) EE200300015A (en)
HU (1) HUP0301742A3 (en)
IL (1) IL153325A0 (en)
IS (1) IS6668A (en)
MX (1) MXPA02012903A (en)
NO (1) NO20030055L (en)
NZ (1) NZ522661A (en)
PL (1) PL359181A1 (en)
RU (1) RU2003103603A (en)
SK (1) SK52003A3 (en)
WO (1) WO2002008213A1 (en)

Families Citing this family (306)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
SE9903544D0 (en) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
AR028948A1 (en) 2000-06-20 2003-05-28 Astrazeneca Ab NEW COMPOUNDS
US6720323B2 (en) 2000-07-07 2004-04-13 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
SE0003828D0 (en) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
CN101607958A (en) 2002-02-01 2009-12-23 阿斯特拉曾尼卡有限公司 Quinazoline compound
GB0217431D0 (en) 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
DE60318219T2 (en) 2002-08-24 2009-01-15 Astrazeneca Ab Pyrimidine derivatives as modulators of the activity of chemokine receptors
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
DK1847539T3 (en) 2002-12-24 2009-11-09 Astrazeneca Ab Quinazoline derivatives
WO2004078126A2 (en) 2003-02-28 2004-09-16 Oxigene, Inc. Compositions and methods with enhanced therapeutic activity
SE0301010D0 (en) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301569D0 (en) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
WO2005051302A2 (en) 2003-11-19 2005-06-09 Array Biopharma Inc. Bicyclic inhibitors of mek and methods of use thereof
GB0328243D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Methods
EP1732920B1 (en) 2004-01-05 2011-03-09 AstraZeneca AB Thiophene derivatives as chk 1 inhibitors
SE0401657D0 (en) 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
EP1809624B1 (en) 2004-08-28 2013-11-20 AstraZeneca AB Pyrimidine sulphonamide derivatives as chemokine receptor modulators
RS52036B (en) 2004-12-21 2012-04-30 Medimmune Limited Antibodies directed to angiopoietin-2 and uses thereof
ES2375735T3 (en) 2005-02-04 2012-03-05 Astrazeneca Ab USEFUL PIRAZOLILAMINOPIRIDINE DERIVATIVES AS QUINASE INHIBITORS.
CA2608201C (en) 2005-05-18 2013-12-31 Array Biopharma Inc. Heterocyclic inhibitors of mek and methods of use thereof
EP2402316A1 (en) 2005-07-21 2012-01-04 AstraZeneca AB (Publ) Piperidine derivatives
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
JPWO2007034817A1 (en) 2005-09-22 2009-03-26 大日本住友製薬株式会社 New adenine compounds
WO2007034916A1 (en) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. Novel adenine compound
EP1939201A4 (en) 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co Novel adenine compound
US20090192153A1 (en) 2005-09-22 2009-07-30 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel adenine compound
EP1939199A4 (en) 2005-09-22 2010-10-20 Dainippon Sumitomo Pharma Co Novel adenine compound
US8148572B2 (en) 2005-10-06 2012-04-03 Astrazeneca Ab Compounds
EP2388259A1 (en) 2005-10-28 2011-11-23 AstraZeneca AB 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
ZA200804498B (en) 2005-11-15 2009-07-29 Array Biopharma Inc N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ERBB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
TW200730512A (en) 2005-12-12 2007-08-16 Astrazeneca Ab Novel compounds
EP1979001B1 (en) 2005-12-13 2012-04-11 Medimmune Limited Binding proteins specific for insulin-like growth factors and uses thereof
ES2380683T3 (en) 2005-12-15 2012-05-17 Astrazeneca Ab Diphenyl ethers, amides, sulphides and substituted methanes for the treatment of respiratory disease
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
EP2125722A2 (en) 2006-05-26 2009-12-02 AstraZeneca AB Bi-aryl or aryl-heteroaryl substituted indoles
CL2007002225A1 (en) 2006-08-03 2008-04-18 Astrazeneca Ab SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A
DE102006037478A1 (en) 2006-08-10 2008-02-14 Merck Patent Gmbh 2- (Heterocyclylbenzyl) -pyridazinone derivatives
HUE033894T2 (en) 2006-08-23 2018-01-29 Kudos Pharm Ltd 2-methylmorpholine pyrido-,pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
ES2385681T3 (en) 2006-12-19 2012-07-30 Astrazeneca Ab Quinuclidinol derivatives as muscarinic receptor antagonists
CL2008000191A1 (en) 2007-01-25 2008-08-22 Astrazeneca Ab COMPOUNDS DERIVED FROM 4-AMINO-CINNOTINA-3-CARBOXAMIDA; CSF-1R QUINASA INHIBITORS; YOUR PREPARATION PROCESS; AND ITS USE TO TREAT CANCER.
AR065784A1 (en) 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co DERIVATIVES OF 8-OXO ADENINE, DRUGS THAT CONTAIN THEM AND USES AS THERAPEUTIC AGENTS FOR ALLERGIC, ANTIVIRAL OR ANTIBACTERIAL DISEASES.
JPWO2008114819A1 (en) 2007-03-20 2010-07-08 大日本住友製薬株式会社 New adenine compounds
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
DE102007025718A1 (en) 2007-06-01 2008-12-04 Merck Patent Gmbh pyridazinone derivatives
DE102007025717A1 (en) 2007-06-01 2008-12-11 Merck Patent Gmbh Aryl ether pyridazinone derivatives
DE102007026341A1 (en) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
UA100983C2 (en) 2007-07-05 2013-02-25 Астразенека Аб Biphenyloxypropanoic acid as crth2 modulator and intermediates
DE102007032507A1 (en) 2007-07-12 2009-04-02 Merck Patent Gmbh pyridazinone derivatives
DE102007038957A1 (en) 2007-08-17 2009-02-19 Merck Patent Gmbh 6-thioxo-pyridazine derivatives
DE102007041115A1 (en) 2007-08-30 2009-03-05 Merck Patent Gmbh Thiadiazinonderivate
MX2010003698A (en) 2007-10-04 2010-04-21 Astrazeneca Ab Steroidal [3, 2-c] pyrazole compounds, with glucocorticoid activity.
RS53552B1 (en) 2007-10-11 2015-02-27 Astrazeneca Ab Pyrrolo[2,3-d]pyrimidin derivatives as protein kinase b inhibitors
EP2245064B1 (en) 2007-12-21 2014-07-23 Medimmune Limited BINDING MEMBERS FOR INTERLEUKIN-4 RECEPTOR ALPHA (IL-4Ralpha)
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
DE102007061963A1 (en) 2007-12-21 2009-06-25 Merck Patent Gmbh pyridazinone derivatives
ES2394547T3 (en) 2008-02-06 2013-02-01 Astrazeneca Ab Compounds
WO2009108670A1 (en) 2008-02-28 2009-09-03 Merck Serono S.A. Protein kinase inhibitors and use thereof
DE102008019907A1 (en) 2008-04-21 2009-10-22 Merck Patent Gmbh pyridazinone derivatives
BRPI0912103A2 (en) 2008-05-27 2021-04-20 Astrazeneca Ab phenoxypyridinylamide derivatives and their use in the treatment of pde4-mediated disease states
DE102008025750A1 (en) 2008-05-29 2009-12-03 Merck Patent Gmbh Dihydropyrazolderivate
DE102008028905A1 (en) 2008-06-18 2009-12-24 Merck Patent Gmbh 3- (3-pyrimidin-2-yl-benzyl) - [1,2,4] triazolo [4,3-b] pyridazine derivatives
DE102008029734A1 (en) 2008-06-23 2009-12-24 Merck Patent Gmbh Thiazolyl-piperidine derivatives
TWI461423B (en) 2008-07-02 2014-11-21 Astrazeneca Ab Thiazolidinedione compounds useful in the treatment of pim kinase related conditions and diseases
DE102008037790A1 (en) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclic triazole derivatives
DE102008038221A1 (en) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-azaindole derivatives
CA2735900A1 (en) 2008-09-19 2010-03-25 Medimmune, Llc Antibodies directed to dll4 and uses thereof
DE102008052943A1 (en) 2008-10-23 2010-04-29 Merck Patent Gmbh azaindole derivatives
WO2010067102A1 (en) 2008-12-09 2010-06-17 Astrazeneca Ab Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders
CN104860913B (en) 2008-12-11 2018-05-04 艾克赛特药品有限公司 The crystal form of genistein
US7863325B2 (en) 2008-12-11 2011-01-04 Axcentua Pharmaceuticals Ab Crystalline genistein sodium salt dihydrate
US20100152197A1 (en) 2008-12-15 2010-06-17 Astrazeneca Ab (4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives
AU2009333653B2 (en) 2008-12-17 2015-09-10 Merck Patent Gmbh C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof
CA2745085C (en) 2008-12-18 2018-03-06 Merck Patent Gmbh Tricyclic azaindoles
DE102008063667A1 (en) 2008-12-18 2010-07-01 Merck Patent Gmbh 3- (3-pyrimidin-2-yl-benzyl) - ° [1,2,4] triazolo [4,3-b] pyrimidine derivatives
TW201028410A (en) 2008-12-22 2010-08-01 Astrazeneca Ab Chemical compounds 610
US20120114667A1 (en) 2008-12-23 2012-05-10 Medimmune Limited TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
DE102008062825A1 (en) 2008-12-23 2010-06-24 Merck Patent Gmbh 3- (3-pyrimidin-2-yl-benzyl) - [1,2,4] triazolo [4,3-b] pyridazine derivatives
DE102008062826A1 (en) 2008-12-23 2010-07-01 Merck Patent Gmbh pyridazinone derivatives
DE102009003954A1 (en) 2009-01-07 2010-07-08 Merck Patent Gmbh pyridazinone derivatives
DE102009003975A1 (en) 2009-01-07 2010-07-08 Merck Patent Gmbh Benzothiazolonderivate
DE102009004061A1 (en) 2009-01-08 2010-07-15 Merck Patent Gmbh pyridazinone derivatives
WO2010089580A1 (en) 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
AU2010212590B2 (en) 2009-02-10 2013-01-10 Astrazeneca Ab Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
GB0905127D0 (en) 2009-03-25 2009-05-06 Pharminox Ltd Novel prodrugs
UY32520A (en) 2009-04-03 2010-10-29 Astrazeneca Ab COMPOUNDS THAT HAVE AGONIST ACTIVITY OF THE GLUCOCORTICOESTEROID RECEPTOR
US8389580B2 (en) 2009-06-02 2013-03-05 Duke University Arylcyclopropylamines and methods of use
US20100317593A1 (en) 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801
DE102009043260A1 (en) 2009-09-28 2011-04-28 Merck Patent Gmbh Pyridinyl-imidazolone derivatives
MX2012003644A (en) 2009-10-02 2012-04-30 Astrazeneca Ab 2-pyridone compounds used as inhibitors of neutrophil elastase.
DE102009049679A1 (en) 2009-10-19 2011-04-21 Merck Patent Gmbh Pyrazolopyrimidinderivate
WO2011048409A1 (en) 2009-10-20 2011-04-28 Astrazeneca Ab Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US8399460B2 (en) 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
MX2012005329A (en) 2009-11-18 2012-05-29 Astrazeneca Ab Benzoimidazole compounds and uses thereof.
DK3279215T3 (en) 2009-11-24 2020-04-27 Medimmune Ltd TARGETED BINDING AGENTS B7-H1
EP2507237A1 (en) 2009-12-03 2012-10-10 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines which act via toll - like receptors (tlr)
DE102009058280A1 (en) 2009-12-14 2011-06-16 Merck Patent Gmbh thiazole
EP2513057B1 (en) 2009-12-14 2013-09-04 Merck Patent GmbH Sphingosine kinase inhibitors
JP2013514287A (en) 2009-12-17 2013-04-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Inhibitors of sphingosine kinase
ES2654584T3 (en) 2010-01-15 2018-02-14 Suzhou Neupharma Co., Ltd Certain chemical entities, compositions and methods
AU2011208530A1 (en) 2010-01-19 2012-08-09 Astrazeneca Ab Pyrazine derivatives
WO2011095807A1 (en) 2010-02-07 2011-08-11 Astrazeneca Ab Combinations of mek and hh inhibitors
WO2011114148A1 (en) 2010-03-17 2011-09-22 Astrazeneca Ab 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
US20130059916A1 (en) 2010-05-26 2013-03-07 Stephane Rocchi Biguanide compounds and its use for treating cancer
WO2011154677A1 (en) 2010-06-09 2011-12-15 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
SA111320519B1 (en) 2010-06-11 2014-07-02 Astrazeneca Ab Pyrimidinyl Compounds for Use as ATR Inhibitors
GB201009801D0 (en) 2010-06-11 2010-07-21 Astrazeneca Ab Compounds 950
TW201219383A (en) 2010-08-02 2012-05-16 Astrazeneca Ab Chemical compounds
TWI535712B (en) 2010-08-06 2016-06-01 阿斯特捷利康公司 Chemical compounds
DE102010034699A1 (en) 2010-08-18 2012-02-23 Merck Patent Gmbh pyrimidine derivatives
WO2012027957A1 (en) 2010-08-28 2012-03-08 Suzhou Neupharma Co., Ltd. Bufalin derivatives, pharmaceutical compositions and use thereof
GB201016442D0 (en) 2010-09-30 2010-11-17 Pharminox Ltd Novel acridine derivatives
DE102010048800A1 (en) 2010-10-20 2012-05-10 Merck Patent Gmbh quinoxaline
DE102010049595A1 (en) 2010-10-26 2012-04-26 Merck Patent Gmbh quinazoline derivatives
WO2012067269A1 (en) 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Aminoalkoxyphenyl compounds and their use in the treatment of disease
WO2012066336A1 (en) 2010-11-19 2012-05-24 Astrazeneca Ab Benzylamine compounds as toll -like receptor 7 agonists
WO2012066335A1 (en) 2010-11-19 2012-05-24 Astrazeneca Ab Phenol compounds als toll -like receptor 7 agonists
WO2012067268A1 (en) 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Cyclic amide compounds and their use in the treatment of disease
ES2575688T3 (en) 2010-12-16 2016-06-30 Sumitomo Dainippon Pharma Co., Ltd. Imidazo [4,5-c] quinolin-1-yl derivative useful in therapy
EP2651943B1 (en) 2010-12-17 2017-03-22 Sumitomo Dainippon Pharma Co., Ltd. Purine derivatives
CA2822515C (en) 2010-12-20 2023-04-25 Medimmune Limited Anti-il-18 antibodies and their uses
EP2670763B1 (en) 2011-02-02 2018-08-01 Suzhou Neupharma Co., Ltd Certain chemical entities, compositions, and methods
CA2827172C (en) 2011-02-17 2019-02-26 Cancer Therapeutics Crc Pty Limited Selective fak inhibitors
US20130324532A1 (en) 2011-02-17 2013-12-05 Cancer Therapeutics Crc Pty Limited Fak inhibitors
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
US8530470B2 (en) 2011-04-13 2013-09-10 Astrazeneca Ab Chromenone derivatives
WO2012175991A1 (en) 2011-06-24 2012-12-27 Pharminox Limited Fused pentacyclic anti - proliferative compounds
US20140227293A1 (en) 2011-06-30 2014-08-14 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
MY180039A (en) 2011-07-12 2020-11-20 Astrazeneca Ab N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator
RS60190B1 (en) 2011-07-27 2020-06-30 Astrazeneca Ab 2-(2,4,5-substituted-anilino)pyrimidine derivatives as egfr modulators useful for treating cancer
DE102011111400A1 (en) 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclic heteroaromatic compounds
WO2013032951A1 (en) 2011-08-26 2013-03-07 Neupharma, Inc. Certain chemical entities, compositions, and methods
US9328081B2 (en) 2011-09-01 2016-05-03 Neupharma, Inc. Certain chemical entities, compositions, and methods
WO2013040515A1 (en) 2011-09-14 2013-03-21 Neupharma, Inc. Certain chemical entities, compositions, and methods
US9249110B2 (en) 2011-09-21 2016-02-02 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors
WO2013045955A1 (en) 2011-09-29 2013-04-04 The University Of Liverpool Prevention and/or treatment of cancer and/or cancer metastasis
US9249111B2 (en) 2011-09-30 2016-02-02 Neupharma, Inc. Substituted quinoxalines as B-RAF kinase inhibitors
US20130178520A1 (en) 2011-12-23 2013-07-11 Duke University Methods of treatment using arylcyclopropylamine compounds
WO2013112950A2 (en) 2012-01-25 2013-08-01 Neupharma, Inc. Certain chemical entities, compositions, and methods
AU2012367141B2 (en) 2012-01-28 2016-12-22 Merck Patent Gmbh Triazolo[4,5-d]pyrimidine derivatives
WO2013117285A1 (en) 2012-02-09 2013-08-15 Merck Patent Gmbh Furo [3, 2 - b] - and thieno [3, 2 - b] pyridine derivatives as tbk1 and ikk inhibitors
US9339503B2 (en) 2012-02-09 2016-05-17 Merck Patent Gmbh Tetrahydro-quinazolinone derivatives as TANK and PARP inhibitors
WO2013126132A1 (en) 2012-02-21 2013-08-29 Merck Patent Gmbh Cyclic diaminopyrimidine derivatives
WO2013124026A1 (en) 2012-02-21 2013-08-29 Merck Patent Gmbh 8 - substituted 2 -amino - [1,2,4] triazolo [1, 5 -a] pyrazines as syk tryrosine kinase inhibitors and gcn2 serin kinase inhibitors
JP6097770B2 (en) 2012-02-21 2017-03-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Furopyridine derivatives
US20150051202A1 (en) 2012-03-07 2015-02-19 Merck Patent Gmbh Triazolopyrazine derivatives
CN104169284B (en) 2012-03-28 2017-03-29 默克专利股份公司 Bicyclic pyrazinone derivatives
WO2013144532A1 (en) 2012-03-30 2013-10-03 Astrazeneca Ab 3 -cyano- 5 -arylamino-7 -cycloalkylaminopyrrolo [1, 5 -a] pyrimidine derivatives and their use as antitumor agents
JP6007310B2 (en) 2012-04-05 2016-10-12 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Bispecific antibodies against human TWEAK and human IL17 and uses thereof
EP3453713B1 (en) 2012-04-29 2021-09-08 Neupharma, Inc. Bufadienolide compounds substituted in position 3 by an amine group for use in the treatment of cancer
AU2013257018B2 (en) 2012-05-04 2017-02-16 Merck Patent Gmbh Pyrrolotriazinone derivatives
GB201211021D0 (en) 2012-06-21 2012-08-01 Cancer Rec Tech Ltd Pharmaceutically active compounds
ES2673873T3 (en) 2012-07-24 2018-06-26 Merck Patent Gmbh Hydroxystatin derivatives for the treatment of osteoarthritis
EP2882746B1 (en) 2012-08-07 2016-12-07 Merck Patent GmbH Pyridopyrimidine derivatives as protein kinase inhibitors
SG11201500732TA (en) 2012-08-08 2015-02-27 Merck Patent Gmbh (aza-)isoquinolinone derivatives
CN104736533B (en) 2012-08-17 2016-12-07 癌症治疗合作研究中心有限公司 Vegfr3 inhibitor
WO2014041349A1 (en) 2012-09-12 2014-03-20 Cancer Therapeutics Crc Pty Ltd Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
WO2014047648A1 (en) 2012-09-24 2014-03-27 Neupharma, Inc. Certain chemical entities, compositions, and methods
KR102200628B1 (en) 2012-09-26 2021-01-08 메르크 파텐트 게엠베하 Quinazolinone derivatives as parp inhibitors
EP2911692B1 (en) 2012-10-26 2019-08-21 The University of Queensland Use of endocytosis inhibitors and antibodies for cancer therapy
CN104903467B (en) 2012-11-05 2020-09-08 Gmdx私人有限公司 Method for determining cause of somatic mutation
US9725421B2 (en) 2012-11-12 2017-08-08 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors
CA2891484A1 (en) 2012-11-16 2014-05-22 Merck Patent Gmbh 3-aminocyclopentane carboxamide derivatives
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
EP3381917B1 (en) 2013-01-31 2021-09-08 Bellus Health Cough Inc. Imidazopyridine compounds and uses thereof
JP6321685B2 (en) 2013-02-25 2018-05-09 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung 2-Amino-3,4-dihydro-quinazoline derivatives and their use as cathepsin D inhibitors
CN105026397B (en) 2013-03-05 2017-06-30 默克专利股份公司 As 9 (aryl or heteroaryl) 2 (pyrazolyl, pyrrolidinyl or cyclopenta) amino purine derivatives of anticancer
AR095443A1 (en) 2013-03-15 2015-10-14 Fundación Centro Nac De Investig Oncológicas Carlos Iii HEREROCICLES CONDENSED WITH ACTION ON ATR
EP2972394A4 (en) 2013-03-15 2016-11-02 Sloan Kettering Inst Cancer Hsp90-targeted cardiac imaging and therapy
US9937137B2 (en) 2013-03-15 2018-04-10 Neurocentria, Inc. Magnesium compositions and uses thereof for cancers
WO2014161570A1 (en) 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof
US20160115146A1 (en) 2013-06-07 2016-04-28 Universite Catholique De Louvain 3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases
WO2014205511A1 (en) 2013-06-25 2014-12-31 University Of Canberra Methods and compositions for modulating cancer stem cells
RU2718876C2 (en) 2013-08-23 2020-04-15 Ньюфарма, Инк. Certain chemical compounds, compositions and methods
EP3046560B1 (en) 2013-09-18 2021-01-06 EpiAxis Therapeutics Pty Ltd Stem cell modulation ii
US20160298197A1 (en) 2013-10-01 2016-10-13 Queensland University Of Technology Kits and methods for diagnosis, screening, treatment and disease monitoring
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
WO2016029262A1 (en) 2014-08-25 2016-03-03 University Of Canberra Compositions for modulating cancer stem cells and uses therefor
ES2883628T3 (en) 2014-11-17 2021-12-09 Univ Queensland Glycoprotein biomarkers for adenocarcinoma of the esophagus and Barrett's esophagus and their uses
MA41179A (en) 2014-12-19 2017-10-24 Cancer Research Tech Ltd PARG INHIBITOR COMPOUNDS
GB201501870D0 (en) 2015-02-04 2015-03-18 Cancer Rec Tech Ltd Autotaxin inhibitors
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
CA2976227C (en) 2015-02-17 2023-10-24 Neupharma, Inc. Quinazoline derivatives and their use in treatment of cancer
GB201510019D0 (en) 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
CN113336746A (en) 2015-08-04 2021-09-03 常州千红生化制药股份有限公司 N- (pyridin-2-yl) -4- (thiazol-5-yl) pyrimidin-2-amines as therapeutic compounds
JP6850294B2 (en) 2015-08-26 2021-03-31 ジーエムディーエックス カンパニー プロプライエタリー リミテッド How to Detect Cancer Recurrence
JP7412079B2 (en) 2015-12-23 2024-01-12 レプルカ プロプライアタリー リミティド Nucleic acid oligomers and their uses
CN108883155A (en) 2016-02-01 2018-11-23 堪培拉大学 Proteinate and application thereof
EP3417294B8 (en) 2016-02-15 2022-05-04 Astrazeneca AB Methods comprising fixed intermittent dosing of cediranib
US10844067B2 (en) 2016-04-15 2020-11-24 Cancer Research Technology Limited Heterocyclic compounds as RET kinase inhibitors
GB2554333A (en) 2016-04-26 2018-04-04 Big Dna Ltd Combination therapy
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
DK3490565T3 (en) 2016-07-29 2022-07-11 Rapt Therapeutics Inc AZETIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF
EP4006035B1 (en) 2016-08-15 2023-11-22 Neupharma, Inc. Quinazoline derivatives as tyrosine kinase inhibitors for the treatment of cancer
US10919896B2 (en) 2016-09-22 2021-02-16 Cancer Research Technology Limited Preparation and uses of pyrimidinone derivatives
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound
KR102495436B1 (en) 2016-12-05 2023-02-02 에이프로스 테라퓨틱스, 인크. Pyrimidine compounds containing acidic groups
US10786502B2 (en) 2016-12-05 2020-09-29 Apros Therapeutics, Inc. Substituted pyrimidines containing acidic groups as TLR7 modulators
SG11201907095UA (en) 2017-02-01 2019-08-27 Aucentra Therapeutics Pty Ltd DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS
EP3592730B1 (en) 2017-03-09 2021-08-04 Truly Translational Sweden AB Prodrugs of sulfasalazine, pharmaceutical compositions thereof and their use in the treatment of autoimmune disease
GB201704325D0 (en) 2017-03-17 2017-05-03 Argonaut Therapeutics Ltd Compounds
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
CN108864079B (en) 2017-05-15 2021-04-09 深圳福沃药业有限公司 Triazine compound and pharmaceutically acceptable salt thereof
US11161839B2 (en) 2017-05-26 2021-11-02 The Institute Of Cancer Research: Royal Cancer Hospital 2-quinolone derived inhibitors of BCL6
IL270869B2 (en) 2017-05-26 2023-09-01 Cancer Research Tech Ltd Benzimidazolone derived inhibitors of bcl6
US11883405B2 (en) 2017-05-31 2024-01-30 Amplio Pharma Ab Pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy
EP3648797A1 (en) 2017-07-05 2020-05-13 EPOS-Iasis Research and Development, Ltd Multifunctional conjugates
ES2940407T3 (en) 2017-08-01 2023-05-08 Merck Patent Gmbh Thiazolopyridine derivatives as adenosine receptor antagonists
EP3668882A1 (en) 2017-08-18 2020-06-24 Cancer Research Technology Limited Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer
JP7287952B2 (en) 2017-08-21 2023-06-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Benzimidazole derivatives as adenosine receptor antagonists
DK3672951T3 (en) 2017-08-21 2023-11-20 Merck Patent Gmbh QUINOXALINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS
TWI702205B (en) 2017-10-06 2020-08-21 俄羅斯聯邦商拜奧卡德聯合股份公司 Epidermal growth factor receptor inhibitors
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
NL2019801B1 (en) 2017-10-25 2019-05-02 Univ Leiden Delivery vectors
BR112020009055A2 (en) 2017-11-06 2020-11-03 Rapt Therapeutics, Inc. chemokine receptor modulators for positive cancer treatment for epstein-Barr virus
ES2965337T3 (en) 2017-11-23 2024-04-12 Medac Ges Fuer Klinische Spezialpraeparate Mbh Pharmaceutical composition for oral administration containing sulfasalazine and/or an organic salt of sulfasalazine, production process and use
EP3489222A1 (en) 2017-11-23 2019-05-29 medac Gesellschaft für klinische Spezialpräparate mbH Sulfasalazine salts, production processes and uses
EP3740484B1 (en) 2018-01-15 2024-09-11 Aucentra Therapeutics Pty Ltd 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents
GB201801128D0 (en) 2018-01-24 2018-03-07 Univ Oxford Innovation Ltd Compounds
IL276295B2 (en) 2018-01-26 2024-02-01 Rapt Therapeutics Inc Chemokine receptor modulators and uses thereof
WO2019157225A2 (en) 2018-02-08 2019-08-15 Neupharma, Inc. Certain chemical entities, compositions, and methods
WO2019175093A1 (en) 2018-03-12 2019-09-19 Astrazeneca Ab Method for treating lung cancer
MX2020010805A (en) 2018-04-13 2021-01-29 Cancer Research Tech Ltd Bcl6 inhibitors.
CN112423747A (en) 2018-04-27 2021-02-26 云杉生物科学公司 Methods for treating testicular and ovarian adrenal residual tumors
GB201809102D0 (en) 2018-06-04 2018-07-18 Univ Oxford Innovation Ltd Compounds
JP7351859B2 (en) 2018-06-04 2023-09-27 アプロス セラピューティクス, インコーポレイテッド Pyrimidine compounds containing acidic groups useful for treating diseases related to TLR7 regulation
EP3802544A1 (en) 2018-06-05 2021-04-14 RAPT Therapeutics, Inc. Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
ES2971927T3 (en) 2018-09-18 2024-06-10 Hoffmann La Roche Quinazoline derivatives as antitumor agents
WO2020068600A1 (en) 2018-09-24 2020-04-02 Rapt Therapeutics, Inc. Ubiquitin-specific-processing protease 7 (usp7) modulators and uses thereof
US20210361669A1 (en) 2018-10-25 2021-11-25 Merck Patent Gmbh 5-azaindazole derivatives as adenosine receptor antagonists
BR112021007435A2 (en) 2018-10-25 2021-08-03 Merck Patent Gmbh 5-azaindazole derivatives as adenosine receptor antagonists
GB201819126D0 (en) 2018-11-23 2019-01-09 Cancer Research Tech Ltd Inhibitor compounds
WO2020132844A1 (en) 2018-12-25 2020-07-02 中国医学科学院基础医学研究所 Small rna medicament for prevention and treatment of inflammation-related diseases and combination thereof
AR117844A1 (en) 2019-01-22 2021-09-01 Merck Patent Gmbh THIAZOLOPYRIDINE DERIVATIVES AS ANTAGONISTS OF THE ADENOSINE RECEPTOR
JP2022524759A (en) 2019-03-07 2022-05-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Carboxamide-pyrimidine derivative as an SHP2 antagonist
CN111747950B (en) 2019-03-29 2024-01-23 深圳福沃药业有限公司 Pyrimidine derivatives for the treatment of cancer
US20230085408A1 (en) 2019-04-05 2023-03-16 STORM Therapeutics Ltd. Mettl3 inhibitory compounds
CA3127475A1 (en) 2019-04-08 2020-10-15 Merck Patent Gmbh Pyrimidinone derivatives as shp2 antagonists
GB201905328D0 (en) 2019-04-15 2019-05-29 Azeria Therapeutics Ltd Inhibitor compounds
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
GB201908885D0 (en) 2019-06-20 2019-08-07 Storm Therapeutics Ltd Therapeutic compounds
US20220298143A1 (en) 2019-08-31 2022-09-22 Etern Biopharma (Shanghai) Co., Ltd. Pyrazole Derivatives for FGFR Inhibitor and Preparation Method Thereof
TW202120501A (en) 2019-09-20 2021-06-01 美商愛德亞生物科學公司 4-substituted indole and indazole sulfonamido derivatives as parg inhibitors
GB201913988D0 (en) 2019-09-27 2019-11-13 Celleron Therapeutics Ltd Novel treatment
GB201914860D0 (en) 2019-10-14 2019-11-27 Cancer Research Tech Ltd Inhibitor compounds
GB201915829D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915831D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915828D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
KR20220113431A (en) 2019-12-02 2022-08-12 스톰 테라퓨틱스 리미티드 Polyheterocyclic Compounds as METTL3 Inhibitors
GB202004960D0 (en) 2020-04-03 2020-05-20 Kinsenus Ltd Inhibitor compounds
GB202008201D0 (en) 2020-06-01 2020-07-15 Neophore Ltd Inhibitor compounds
GB202012482D0 (en) 2020-08-11 2020-09-23 Univ Of Huddersfield Novel compounds and therapeutic uses thereof
GB202012969D0 (en) 2020-08-19 2020-09-30 Univ Of Oxford Inhibitor compounds
WO2022074379A1 (en) 2020-10-06 2022-04-14 Storm Therapeutics Limited Mettl3 inhibitory compounds
US20240101589A1 (en) 2020-10-08 2024-03-28 Strom Therapeutics Limited Inhibitors of mettl3
US12030888B2 (en) 2021-02-24 2024-07-09 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
GB202102895D0 (en) 2021-03-01 2021-04-14 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
WO2022197641A1 (en) 2021-03-15 2022-09-22 Rapt Therapeutics, Inc. 1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
IL308163A (en) 2021-05-03 2024-01-01 Merck Patent Gmbh Her2 targeting fc antigen binding fragment-drug conjugates
AU2022276958A1 (en) 2021-05-17 2023-12-07 Hk Inno.N Corporation Benzamide derivative, method for preparing same, and pharmaceutical composition for prevention or treatment of cancer containing same as active ingredient
IL308818A (en) 2021-05-25 2024-01-01 Merck Patent Gmbh Egfr targeting fc antigen binding fragment-drug conjugates
GB202107907D0 (en) 2021-06-02 2021-07-14 Storm Therapeutics Ltd Combination therapies
GB202108383D0 (en) 2021-06-11 2021-07-28 Argonaut Therapeutics Ltd Compounds useful in the treatment or prevention of a prmt5-mediated disorder
GB202110373D0 (en) 2021-07-19 2021-09-01 Neophore Ltd Inhibitor compounds
EP4413000A1 (en) 2021-10-04 2024-08-14 FoRx Therapeutics AG N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
WO2023057389A1 (en) 2021-10-04 2023-04-13 Forx Therapeutics Ag Parg inhibitory compounds
GB202117225D0 (en) 2021-11-29 2022-01-12 Neophore Ltd Protac compounds
GB202117224D0 (en) 2021-11-29 2022-01-12 Neophore Ltd Inhibitor compounds
AU2023205435A1 (en) 2022-01-10 2024-08-22 Cancer Research Horizons Substituted heterocycles as hset inhibitors
GB202202006D0 (en) 2022-02-15 2022-03-30 Chancellor Masters And Scholars Of The Univ Of Oxford Anti-cancer treatment
GB202202199D0 (en) 2022-02-18 2022-04-06 Cancer Research Tech Ltd Compounds
WO2023175185A1 (en) 2022-03-17 2023-09-21 Forx Therapeutics Ag 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
WO2023175184A1 (en) 2022-03-17 2023-09-21 Forx Therapeutics Ag 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
GB202204935D0 (en) 2022-04-04 2022-05-18 Cambridge Entpr Ltd Nanoparticles
US20230322741A1 (en) 2022-04-06 2023-10-12 Rapt Therapeutics, Inc. Chemokine receptor modulators and uses thereof
WO2023218201A1 (en) 2022-05-11 2023-11-16 Cancer Research Technology Limited Ikk inhibitors
GB202209404D0 (en) 2022-06-27 2022-08-10 Univ Of Sussex Compounds
WO2024030825A1 (en) 2022-08-01 2024-02-08 Neupharma, Inc Crystalline salts of crystalline salts of (3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-dimethyl-17-(2- oxo-2h-pyran-5-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-3-yl piperazine-1-carboxylate
GB202213162D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Prodrugs
GB202213163D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213166D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213167D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213164D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
WO2024074497A1 (en) 2022-10-03 2024-04-11 Forx Therapeutics Ag Parg inhibitory compound
WO2024094962A1 (en) 2022-11-02 2024-05-10 Cancer Research Technology Limited Pyrido[2,3-d]pyrimidin-2-amine derivatives as egfr inhibitors for the treatment of cancer
WO2024094963A1 (en) 2022-11-02 2024-05-10 Cancer Research Technology Limited 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one and 7-amino-1-pyrimido[4,5-d]pyrimidin-2(1 h)-one derivatives as egfr inhibitors for the treatment of cancer
WO2024099898A1 (en) 2022-11-07 2024-05-16 Merck Patent Gmbh Substituted bi-and tricyclic hset inhibitors
GB202218672D0 (en) 2022-12-12 2023-01-25 Storm Therapeutics Ltd Inhibitory compounds
GB202300881D0 (en) 2023-01-20 2023-03-08 Neophore Ltd Inhibitor compounds
WO2024173530A1 (en) 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Heteroaryl-substituted pyrazolo/imidazo pyridine compounds
WO2024173514A1 (en) 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Amide and ester-substituted imidazopyridine compounds
WO2024173453A1 (en) 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Heteroaryl-substituted imidazopyridine compounds
WO2024173524A1 (en) 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Heteroaryl-substituted benzimidazole compounds
US20240327430A1 (en) 2023-03-10 2024-10-03 Breakpoint Therapeutics Gmbh Novel compounds, compositions, and therapeutic uses thereof
WO2024209035A1 (en) 2023-04-05 2024-10-10 Forx Therapeutics Ag Parg inhibitory compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9714249D0 (en) * 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents

Also Published As

Publication number Publication date
HUP0301742A2 (en) 2003-09-29
JP2004504391A (en) 2004-02-12
IL153325A0 (en) 2003-07-06
EP1301498A1 (en) 2003-04-16
HUP0301742A3 (en) 2005-08-29
EE200300015A (en) 2004-10-15
CZ200331A3 (en) 2003-04-16
BR0112225A (en) 2003-05-06
NZ522661A (en) 2004-07-30
CA2410562A1 (en) 2002-01-31
AU2001266232B2 (en) 2005-09-15
CN1255392C (en) 2006-05-10
CN1440396A (en) 2003-09-03
MXPA02012903A (en) 2004-07-30
SK52003A3 (en) 2003-07-01
NO20030055D0 (en) 2003-01-06
WO2002008213A1 (en) 2002-01-31
IS6668A (en) 2003-01-03
NO20030055L (en) 2003-01-06
KR20030022264A (en) 2003-03-15
PL359181A1 (en) 2004-08-23
RU2003103603A (en) 2004-08-20

Similar Documents

Publication Publication Date Title
IL153325A0 (en) Colchinol derivatives as angiogenesis inhibitors
IL153484A0 (en) Colchinol derivatives as angiogenesis inhibitors
SI1686119T1 (en) Pyrimidine-5-one derivatives as LDL-PLA2 inhibitors
EG22695A (en) Novel phenyl-propargylether derivatives
AU6053701A (en) 2-aminocarbonyl-9h-purine derivatives
HRP20030055A2 (en) 4-phenyl-pyridine derivatives
IL150841A0 (en) 1h-imidazopyridine derivatives
AU2002216314A1 (en) Heterocyclic angiogenesis inhibitors
HK1061018A1 (en) Substituted c-cyclohexylmethylamine derivatives
AU8993701A (en) Substituted 1-aminobutan-3-ol derivatives
IL150557A0 (en) Substituted aminomethyl-phenyl-cyclohexane derivatives
PL356565A1 (en) Aminosulfonylbiphenyl derivatives
IL150558A0 (en) Aminomethyl-phenyl-cyclohexanone derivatives
IL155104A0 (en) 5-amino-1-pentene-3-ol substituted derivatives
EP1408955A4 (en) Novel metallotexaphyrin derivatives
EP1354589A4 (en) Angiogenesis inhibitors
IL151598A0 (en) 2-phenylpyran-4-one derivatives
AUPR015600A0 (en) Angiogenesis inhibitors
SI1246793T1 (en) Substituted aminomethyl-phenyl-cyclohexane derivatives
SI1322590T1 (en) 5-amino-1-pentene-3-ol substituted derivatives
GB0021639D0 (en) Maurotoxin derivatives
HK1054937A1 (en) 1-Methylcarbapenem derivatives